Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,585 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03503604 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | unknown | Phase 1 | 18 | SuZhou Stainwei Biotech Inc.INDUSTRY | 1 | Apr 20, 2018 | clinicaltrials |
| NCT01975454 | Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 62 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01462474 | Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma(FMTN-I-LNPC) | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01762280 | A Phase I Study of Famitinib Malate in Patients With Solid Tumor | completed | Phase 1 | 55 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01534585 | Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 48 | Taizhou HospitalOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03188497 | Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial | completed | Phase 1 | 17 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT03474289 | Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors | unknown | Phase 1 | 134 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 22, 2018 | clinicaltrials |
| NCT02921984 | Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors | completed | Phase 1 | 20 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03468153 | Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma | unknown | Phase 1 / Phase 2 | 10 | Ruijin HospitalOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT03439761 | An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 125 | SciClone PharmaceuticalsINDUSTRY | 1 | Mar 16, 2018 | clinicaltrials |
| NCT03463928 | A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03456466 | Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 122 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT03453034 | Tolerance and Pharmacokinetics of TQ-B3233 | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT03453255 | DCHA as Postremission Therapy for AML With t(8;21) | unknown | Phase 1 / Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT03447145 | A New Drug Used for Advanced Cancer | unknown | Phase 1 | 50 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | unknown | Phase 1 / Phase 2 | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 26, 2018 | clinicaltrials |
| NCT03427684 | Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 18 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT03245307 | A Study To Test The Effect Of Apatinib On P450 Enzymes | unknown | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 7, 2018 | clinicaltrials |
| NCT03424928 | A Pilot Bioequivalence Study of Pomalidomide | completed | Phase 1 | 12 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 7, 2018 | clinicaltrials |
| NCT02958384 | A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03404414 | Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT | unknown | Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT01781520 | Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 47 | Capital Medical UniversityOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03175705 | Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC | unknown | Phase 1 | 18 | Beijing YouAn HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03403595 | 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03398967 | A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT02577458 | Study of the Combination of CM082 With Everolimus in Patients With mRCC | unknown | Phase 1 | 18 | AnewPharmaINDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT02924753 | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03383952 | A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03383965 | CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas | unknown | Phase 1 | 20 | Immune Cell, Inc.INDUSTRY | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03299738 | A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL | unknown | Phase 1 | 10 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03313219 | Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China | unknown | Phase 1 | 20 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02940132 | A Study of SC10914 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT02122822 | Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96 | completed | Phase 1 | 20 | Cure&Sure Biotech Co., LTDINDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03344705 | Safety and Efficacy Evaluation of IM19 Cells | unknown | Phase 1 | 20 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03321448 | TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT02468284 | Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer | completed | Phase 1 | 15 | Ferring PharmaceuticalsINDUSTRY | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03320772 | TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer | unknown | Phase 1 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02446574 | Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 33 | Chinese Academy of Medical SciencesOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT03263208 | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. | unknown | Phase 1 / Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 20, 2017 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03311789 | Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT03308682 | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT03001609 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC | completed | Phase 1 | 7 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT02752516 | A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics | unknown | Phase 1 | 16 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT03019276 | A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics | unknown | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT03099330 | A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics | unknown | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials